|Videos|December 22, 2019
Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03
Author(s)Sponsored Content
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ASCO 2026 That Patients Should Know
2
Pumitamig Shows 70% Response in Advanced Lung Cancer Regardless of PD-L1 Status
3
Nurse-Led Quality Initiative Reduces CLABSI Risk in Hematologic Cancer Care
4
A Cancer Survivor Reflects on Organ Donation
5